|View printer-friendly version|
|November 07, 2002 4:24 p.m.|
|Teva to Terminate the Promise Trial Following Unfavorable Interim Analysis|
Jerusalem, Israel, November 7, 2002 - Teva Pharmaceutical Industries Ltd. (Nasdaq: Teva) announced that an interim analysis of its clinical trial on primary progressive multiple sclerosis showed that it was improbable that the study at its current protocol, would reach statistical significance. The scheduled interim analysis by the study's data safety monitoring committee came two years into the three-year study. There have been no safety concerns about treatment with COPAXONE®(glatiramer acetate for injection).